TLDR
- AbbVie finalized the Apogee Therapeutics purchase at $135.11 per share, representing a total transaction value of roughly $10.9 billion
- Zumilokibart, Apogee’s flagship candidate, is an IL-13 inhibitor that delivered skin clearance in approximately two-thirds of atopic dermatitis patients during Phase 2 testing
- Additional assets include APG273, a dual-mechanism treatment combining IL-13 and TSLP blockade for asthma management
- The transaction is projected to reduce adjusted EPS by $0.14 this year and $0.46 next year, with positive contribution not anticipated before 2032
- The company maintained its 2026 adjusted diluted EPS forecast in the $13.87 to $14.07 range
On September 3, 2026, AbbVie (ABBV) finalized its acquisition of Apogee Therapeutics, delivering $135.11 in cash per share. The all-cash transaction valued the biotech company at approximately $10.9 billion in total equity. Apogee’s shares ceased public trading following the deal’s completion.
This acquisition brings a collection of immunology-focused assets into AbbVie’s therapeutic arsenal. The acquired programs concentrate on immune-mediated and inflammatory conditions such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease.
Zumilokibart stands out as Apogee’s most advanced candidate. This monoclonal antibody selectively inhibits IL-13, a key cytokine responsible for driving type 2 inflammatory responses. The molecule features an extended half-life engineered to enable reduced dosing frequency compared to existing therapeutic options.
Clinical data from Phase 2 trials demonstrated that roughly two-thirds of patients with atopic dermatitis achieved clear skin by week 16 while receiving zumilokibart. Trial participants also experienced notable improvements in pruritus relief and overall symptom management.
Extended follow-up findings from the same study validate maintenance regimens administered either every three months or just twice annually. Such infrequent administration schedules may offer significant practical advantages for both patients and healthcare providers.
Examining the Acquired Pipeline Assets
In addition to zumilokibart, the transaction includes APG273, an innovative combination therapy that links zumilokibart with APG333. APG333 functions as a TSLP antagonist, neutralizing a critical upstream inflammatory mediator in pulmonary tissue.
Early-stage Phase 1 results demonstrated that APG333 achieved sustained suppression of inflammatory biomarkers lasting up to six months following a single administration. Encouraging preliminary findings from a Phase 1b asthma trial evaluating zumilokibart provide additional validation for the dual-target strategy.
The combined APG273 regimen has the potential to deliver asthma control with dosing just four times yearly or even semi-annually. This positions the therapy as a competitive alternative to current biologics in an expanding therapeutic market.
AbbVie CEO Robert Michael emphasized that integrating Apogee’s innovative science with AbbVie’s established commercialization infrastructure should accelerate clinical development timelines and broaden patient access.
Financial Impact on AbbVie’s Bottom Line
The acquisition carries near-term financial headwinds. AbbVie projects the transaction will decrease adjusted diluted EPS by $0.14 in 2026 and approximately $0.46 in 2027.
The deal won’t become accretive to earnings until 2032, representing an extended investment horizon. Despite these projections, AbbVie left its existing financial outlook unchanged following the transaction’s close.
Management reiterated the full-year 2026 adjusted diluted EPS forecast range of $13.87 to $14.07. The third-quarter 2026 adjusted diluted EPS outlook also remained steady at $3.84 to $3.88.
The current 2026 forecast incorporates $0.58 per share in negative IPR&D and milestone charges recognized during the first half of the year. Additional IPR&D or milestone-related expenses arising after the second quarter are excluded from official guidance due to forecasting uncertainty.
AbbVie highlighted that its immunology portfolio currently serves over 1 million patients globally, with regulatory approvals spanning 19 distinct immune-mediated conditions across more than 175 markets worldwide.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
